Journal
METABOLITES
Volume 11, Issue 3, Pages -Publisher
MDPI
DOI: 10.3390/metabo11030129
Keywords
colorectal cancer; recurrence; targeted metabolomics
Categories
Funding
- Wereld Kanker Onderzoek Fonds (WKOF) & World Cancer Research Fund International (WCRF International)
- World Cancer Research Fund International Regular Grant Programme (WKOF/WCRF, the Netherlands) [2014/1179]
- Alpe d'Huzes/Dutch Cancer Society (KWF Kankerbestrijding, the Netherlands) [UM 2012-5653, UW 2013-5927, UW 2015-7946]
- Netherlands Organization for Health Research and Development (ZonMw, the Netherlands)
- Stichting Alpe d'HuZes within the research program 'Leven met kanker' of the Dutch Cancer Society [UM-2010-4867, UM-2012-5653]
- Kankeronderzoekfonds Limburg as part of Health Foundation Limburg [00005739]
- Wereld Kanker Onderzoek Fonds (WKOF), as part of the World Cancer Research Fund International grant programme [2016/1620]
- ERA-NET on Translational Cancer Research (TRANSCAN/Dutch Cancer Society, the Netherlands) [UW 2013-6397, UM 2014-6877, UW 2014-6877]
- Wereld Kanker Onderzoek Fonds (WKOF), as part of theWorld Cancer Research Fund International grant programme [2016/1620]
- ERA-NET on Translational Cancer Research (TRANSCAN) [01KT1503]
- National Cancer Institute [R01 CA189184]
- Stiftung Lebensblicke
- Matthias Lackas Foundation
- National Institutes of Health/NationalCancer Institute [U01CA206110, R01CA189184, R01 CA207371]
- Huntsman Cancer Foundation
- Austrian Science Fund (FWF) [1578-B19]
- National Cancer Institute (France) [2014-007]
- National Institutes of Health under Ruth L. Kirschstein National Research Service Award from the National Human Genome Research Institute [T32 HG008962]
Ask authors/readers for more resources
This study aimed to investigate the associations of metabolites with risk of recurrence in stage II/III CRC patients, but no statistically significant associations were found. Further follow-up in larger studies is needed to confirm these results.
The identification of patients at high-risk for colorectal cancer (CRC) recurrence remains an unmet clinical need. The aim of this study was to investigate associations of metabolites with risk of recurrence in stage II/III CRC patients. A targeted metabolomics assay (128 metabolites measured) was performed on pre-surgery collected EDTA plasma samples from n = 440 newly diagnosed stage II/III CRC patients. Patients have been recruited from four prospective cohort studies as part of an international consortium: Metabolomic profiles throughout the continuum of CRC (MetaboCCC). Cox proportional hazard models were computed to investigate associations of metabolites with recurrence, adjusted for age, sex, tumor stage, tumor site, body mass index, and cohort; false discovery rate (FDR) was used to account for multiple testing. Sixty-nine patients (15%) had a recurrence after a median follow-up time of 20 months. We identified 13 metabolites that were nominally associated with a reduced risk of recurrence. None of the associations were statistically significant after controlling for multiple testing. Pathway topology analyses did not reveal statistically significant associations between recurrence and alterations in metabolic pathways (e.g., sphingolipid metabolism p = 0.04; pFDR = 1.00). To conclude, we did not observe statistically significant associations between metabolites and CRC recurrence using a well-established metabolomics assay. The observed results require follow-up in larger studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available